• With the introduction of anthracycline-based regimens, 5-year survival rates have significantly improved in patients with early-stage breast cancer. (carcinogenesis.com)
  • We also review the data the efficacy and safety of anthracycline-based and nonanthracycline-based adjuvant chemotherapy regimens combined with trastuzumab, and optimum chemotherapy regimens in small HER2-positive tumors. (carcinogenesis.com)
  • Docetaxel-based chemotherapy regimens have substantially improved survival and recurrence rates for cancer patients. (hindawi.com)
  • Systemic adjuvant chemotherapy with anthracycline- and taxane-containing regimens has become the standard first line treatment for early and metastatic breast cancer [ 5 ], with large phase III randomized trials showing extremely high long-term disease-free survival and overall survival rates (resp. (hindawi.com)
  • In fact, reducing the planned dose intensity of systemic adjuvant chemotherapy regimens by as little as 15% has been shown to significantly reduce time to progression and overall survival rates in women with metastatic breast cancer [ 5 ]. (hindawi.com)
  • G-CSFs have been shown to reduce overall mortality risk [ 8 , 11 ], reduce the incidence of other adverse events (grade 2 or greater anaemia, asthenia, anorexia, myalgia, nail disorders, and oral mucositis) associated with docetaxel-based chemotherapy regimens, and increase health related quality of life and consequently treatment compliance [ 8 , 12 ]. (hindawi.com)
  • Based on this evidence, guidelines published by the American Society of Clinical Oncology and the European Organisation for Research and Treatment of Cancer state that when the overall risk of FN is 20% or greater, especially on "dose dense" regimens, primary prophylaxis with G-CSFs is justified [ 10 , 13 ]. (hindawi.com)
  • Tailoring adjuvant chemotherapy regimens for patients with triple negative breast cancer. (curehunter.com)
  • These patients would then be treated with sequential single-agent chemotherapy regimens, similar to the treatment paradigm for patients whose tumors do not express hormone receptor. (fda.gov)
  • The incidence and severity was highest in patients receiving Herceptin with anthracycline-containing chemotherapy regimens. (herceptin.com)
  • Daiichi Sankyo (TSE: 4568) and AstraZeneca's (LSE/STO/Nasdaq: AZN) trastuzumab deruxtecan has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received one or more prior anti-HER2-based regimens. (tt.se)
  • as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. (who.int)
  • An updated search was carried out in the Cochrane Breast Cancer Group's Specialised Register (20 May 2011), MEDLINE (14 December 2011), EMBASE (20 May 2011) and World Health Organization (WHO) International Clinical Trials Registry Platform (20 May 2011). (cochrane.org)
  • Olaparib in combination with temozolomide demonstrated substantial clinical activity in relapsed small cell lung cancer. (wikipedia.org)
  • Over 100 free commonly used clinical formulas and calculator tools to help diagnose, treat, prevent, and determine prognosis of patients at point of care. (guidelinecentral.com)
  • Identify clinical preventive services that are appropriate for your patients. (guidelinecentral.com)
  • Treatment protocols for cancer of unknown primary (CUP) are provided below, including treatment for metastasis to cervical lymph nodes, in women with isolated axillary adenopathy, for metastatic melanoma to a single nodal site, and for cancer of unknown primary in unselected patients, as well as common chemotherapeutic agents in clinical practice. (medscape.com)
  • Patients with cancer of unknown primary should always be offered clinical trial enrollment as an option for treatment. (medscape.com)
  • The clinical benefit demonstrated by those drugs in advanced disease has triggered several adjuvant and neoadjuvant trials testing them in combination with chemotherapy, but also without conventional chemotherapy, using single or dual HER2-targeting drugs. (carcinogenesis.com)
  • There is strong and consistent clinical evidence to show that granulocyte-colony stimulating factors (G-CSFs) reduce the risk of chemotherapy-induced neutropenia and therefore complicated neutropenia and can be used to maintain chemotherapy at the desired dose intensity or density and minimize delays in treatment [ 11 ]. (hindawi.com)
  • Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003). (curehunter.com)
  • This additional experience prepares the surgical oncologist to take the lead where appropriate in the multidisciplinary management of solid tumors and to develop either a clinical or translational research program into his cancer of interest. (blogspot.com)
  • Objective: To determine whether CYP2D6 variation is associated with clinical outcomes in women receiving adjuvant tamoxifen. (elsevierpure.com)
  • Conclusion: Among women with breast cancer treated with tamoxifen, there was an association between CYP2D6 variation and clinical outcomes, such that the presence of 2 functional CYP2D6 alleles was associated with better clinical outcomes and the presence of nonfunctional or reduced-function alleles with worse outcomes. (elsevierpure.com)
  • The FDA's acceptance of our application adds to our momentum of advancing new treatment options to address the most challenging cancers facing women," said Dr. Scot Ebbinghaus, vice president, clinical research, Merck Research Laboratories. (businesswire.com)
  • Merck is rapidly advancing a broad portfolio in gynecologic and breast cancers with an extensive clinical development program for KEYTRUDA and several other investigational and approved medicines across these areas. (businesswire.com)
  • The biopharmaceutical company Antisense Pharma today presents trabedersen complete data from its clinical Phase I/II study in patients with advanced pancreatic cancer, malignant melanoma or colorectal cancer at the international cancer congress ASCO 2012 in Chicago, USA. (med-chemist.com)
  • Dr Sarah Bowden is the Director of Operations at the Cancer Research UK Clinical Trials Unit (CRCTU) at the University of Birmingham. (birmingham.ac.uk)
  • She has a specific interest in late phase cancer clinical trials research and acts as the Unit's pharmacovigilance lead. (birmingham.ac.uk)
  • In addition, she continues to play an active role in the development and management of the unit's late phase cancer research portfolio and has more recently been involved in the development and delivery of a number of COVID-19 clinical trials. (birmingham.ac.uk)
  • She is a member of several clinical trials committees and working groups locally, nationally and internationally including the University of Birmingham Clinical Trials Oversight Committee, the Cancer Research UK Clinical Trials Unit's (CTU) Directors Committee, the National Cancer Research Institute (NCRI) CTU's Operational Leads Committee, and the European Medicines Agency Clinical Trials Information System (CTIS) Stakeholder Group. (birmingham.ac.uk)
  • As a leader in lung cancer research, we continue to try to advance science for our patients by building upon the standard we set several years ago with KEYTRUDA," said Dr. Gregory Lubiniecki, Vice President, Global Clinical Development, Merck Research Laboratories. (streetinsider.com)
  • Merck and Eisai are studying the KEYTRUDA plus LENVIMA combination through the LEAP (LEnvatinib And Pembrolizumab) clinical program in various tumor types, including but not limited to endometrial carcinoma, hepatocellular carcinoma, RCC, head and neck cancer, gastric cancer and esophageal cancer across multiple clinical trials. (streetinsider.com)
  • All patients with breast cancer liver metastases surgically treated in the "Dan Setlacec" Center of Gastrointestinal Disease and Liver Transplantation, the Fundeni Clinical Institute between January 2004 and December 2014 were retrospectively reviewed. (iiarjournals.org)
  • 15,19 Clinical studies have shown that breast or gastric/GEA cancer patients with high HER2 protein overexpression and/or gene amplification benefit most from trastuzumab. (roche.com)
  • Early Breast Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. (roche.com)
  • We also selected articles on BC epidemiology, risk factors, clinical presentation, and cancer control in Africa. (karger.com)
  • The clinical picture of BC differs from that of Western countries due to the high proportion of young patients (on account of the African population with a high proportion of young people) and late presentation. (karger.com)
  • Molecular risk factors for particular patterns of metastastic spread in a clinical population are limited. (biomedcentral.com)
  • A case-control design including 1357 primary breast cancers was used to study three distinct clinical patterns of metastasis, which occur within the first six months of metastatic disease: bone and visceral metasynchronous spread, bone-only, and visceral-only metastasis. (biomedcentral.com)
  • Clinical studies show chemotherapy plus Trastuzumab reduces the risk of breast cancer recurrence in half of the patients with HER2 positive status, compared to chemotherapy alone. (fvhospital.com)
  • Preclinical data and some of the limited available clinical data suggest that loss or inactivation of PTEN, which has been reported in a significant proportion of HER2-positive breast cancers, may result in reduced sensitivity to trastuzumab. (ascopost.com)
  • 2. Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as ≥20 mm with conventional techniques or as ≥10 mm with spiral CT scan, MRI, or calipers by clinical exam. (uchicagomedicine.org)
  • All chapters in this text are written by experts in the field who have research and clinical interest in each of these disease entities, and include the most up-to-date research and clinical information to enhance our understanding and treatment of patients. (nshealth.ca)
  • Clinical staff were invited to access and use patient data in clinical assessments. (bmj.com)
  • In particular, improvement of the clinical notification, patient reminder systems and changes to patient and staff training. (bmj.com)
  • Halofuginone (see structure, below) has been in clinical trials for cancer, but the high-resolution picture of the molecule suggests it has a modularity that would make it useful as a template to create new drugs for numerous other diseases. (med-chemist.com)
  • Dr. Roy Baynes, chief shortcoming president and highest of global clinical enlargement, chief medical dick, Merck Probing Laboratories, insinuated, "Metastatic close cancer is a complex hodgepodge with extant unmet medical girl. (piwip.com)
  • Association of emergence of new mutations in circulating tumuor DNA during chemotherapy with clinical outcome in metastatic colorectal cancer. (cdc.gov)
  • Our data have provided evidence for a comparable prediction of clinical outcome in CMF-treated breast cancer patients using conventional clinical variables and gene expression based markers. (lu.se)
  • Breast cancer is a heterogeneous disease with a large variabil- survival after adjuvant polychemotherapy was 10% (from ity in clinical outcome. (lu.se)
  • Adjuvant polychemotherapy (e.g. with 58% to 68%) for patients under the age of 50.1 Besides an cyclophosphamide, methotrexate and 5-fluorouracil (CMF)) or improvement in clinical outcome, these figures indicate that anthracycline-containing regimes, produce substantial reduc- a large proportion of the patients will never recur after the tion in recurrence and mortality. (lu.se)
  • Non-epithelial ovarian cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. (cancercentrum.se)
  • In breast cancer, the clinical applications of ctDNA are potentially wide-ranging and include screening or early diagnosis, risk stratification and prognostication, monitoring response to neoadjuvant/adjuvant therapy, detection of minimal residual disease (MRD), and molecular profiling and monitoring clonal evolution in metastatic breast cancer (MBC). (medscape.com)
  • In breast cancer, olaparib is approved for gBRCAm HER2-negative metastatic breast cancer patients who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. (wikipedia.org)
  • With the addition of trastuzumab, a monoclonal antibody targeting the human epidermal growth factor receptor-2 (HER2), improvements in overall survival have been observed among patients with advanced HER2-positive disease. (carcinogenesis.com)
  • Subsequently, lapatinib, an orally bioavailable small molecule dual HER2- and EGFR/HER1-specific tyrosine kinase inhibitor, received Food and Drug Administration (FDA) approval in combination with capecitabine for patients with advanced HER2+ breast cancer. (carcinogenesis.com)
  • The FDA also approved 1 year of extended adjuvant neratinib after chemotherapy and a year of trastuzumab for HER2-positive breast cancer on the basis of the ExteNET trial. (carcinogenesis.com)
  • In this article, we review the current data on the therapeutic management of HER2-positive early-stage breast cancer in the adjuvant and neoadjuvant setting. (carcinogenesis.com)
  • One type of breast cancer is identified by the human epidermal growth factor receptor 2 (HER2) gene amplification. (carcinogenesis.com)
  • This subtype accounts for approximately 20%-30% of invasive breast cancers, and until the discovery of effective anti-HER2 therapies ( first of which is trastuzumab), was associated with reduced disease-free survival (DFS), increased risk of metastases, and shorter overall survival (OS). (carcinogenesis.com)
  • Olaparib, which is marketed as Lynparza, was approved for the treatment of patients with HER2 negative metastatic breast cancers that harbor germline BRCA-mutations, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting. (fda.gov)
  • SB: This approval was based on a study called OlympiAD, which was an open-label, multi-center trial that randomized 302 patients 2 to 1 who had germline BRCA mutation and HER2-negative metastatic breast cancer to olaparib tablets, 300 mg orally twice daily, or to their physician's choice of chemotherapy. (fda.gov)
  • Learn about Herceptin's legacy of treating HER2-positive metastatic breast cancer. (herceptin.com)
  • Herceptin is indicated, in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, who have not received prior treatment for metastatic disease. (herceptin.com)
  • 0.0001) in patients with HER2 positive unresectable and/or metastatic breast cancer previously treated with trastuzumab and a taxane. (tt.se)
  • 1 Approximately one in five cases of breast cancer are considered HER2 positive. (tt.se)
  • 2 Despite initial treatment with trastuzumab, pertuzumab and a taxane, patients with HER2 positive metastatic breast cancer will often experience disease progression. (tt.se)
  • This positive CHMP opinion is an important step forward in bringing this potentially practice-changing medicine to patients in Europe to use earlier in the treatment of HER2 positive metastatic breast cancer and builds on the recent approval of trastuzumab deruxtecan in the U.S. (tt.se)
  • This recommendation reflects the transformative progression-free survival benefit seen in the DESTINY-Breast03 trial compared to T-DM1, supporting trastuzumab deruxtecan as a potential new standard of care and setting a new benchmark in the treatment of HER2 positive metastatic breast cancer," said Susan Galbraith, MBBChir, PhD, Executive Vice President, Oncology R&D, AstraZeneca. (tt.se)
  • We did a phase 3 trial to assess a neoadjuvant regimen for HER2-positive breast cancer that replaces traditional systemic chemotherapy with targeted treatment. (nih.gov)
  • Language": "en", "Country": "XG", "Code": "Storage Conditions (Product)" }, { "Name": "Background Information", "Value": "Human epidermal growth factor receptor 2 (HER2) is a member of the epidermal growth factor subfamily of transmembrane receptor tyrosine kinases that mediate the growth, differentiation, and survival of cells. (roche.com)
  • 1,2 Approximately 15 to 30 percent of breast carcinomas demonstrate overexpression of the HER2 protein, amplification of the HER2 gene (ERBB2), or both. (roche.com)
  • 3,4 Knowledge of HER2 gene and/or protein status in invasive breast carcinoma enables clinicians to make more informed decisions to improve the overall management of care for these patients. (roche.com)
  • 5 HER2 status is an established predictive factor for response to HER2 targeted therapy in breast cancer patients. (roche.com)
  • Trastuzumab (Herceptin) is a humanized monoclonal antibody against the extracellular domain of HER2 and has been shown to benefit patients with HER2 positive breast cancer. (roche.com)
  • 8-13 Demonstration of HER2 gene amplification and/or protein overexpression is essential for selecting patients for trastuzumab therapy. (roche.com)
  • However, one of the largest screening datasets which included 3,803 patients with GEA reported that 22 percent of patients tested positive for HER2 protein expression or gene amplification. (roche.com)
  • The HER2 targeted therapy trastuzumab is a mainstay in the management of invasive breast carcinoma and has therapeutic value in the management of gastric/GEA cancer patients overexpressing the receptor. (roche.com)
  • 15,17 Demonstration of HER2 gene amplification and/or protein overexpression is essential for selecting patients for trastuzumab therapy. (roche.com)
  • 1. Moasser MM. The Oncogene Her2: Its Signaling and Transforming Functions and Its Role in Human Cancer Pathogenesis. (roche.com)
  • The Role of Her2, Egfr, and Other Receptor Tyrosine Kinases in Breast Cancer. (roche.com)
  • Her2/Neu Role in Breast Cancer: From a Prognostic Foe to a Predictive Friend. (roche.com)
  • The Evolving Landscape of Her2 Targeting in Breast Cancer. (roche.com)
  • Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. (roche.com)
  • Concurrent administration of anti-HER2 monoclonal antibody and first-line chemotherapy for HER2-overexpressing metastatic breast cancer. (roche.com)
  • Neratinib: Inching Up on the Cure Rate of HER2 + Breast Cancer? (aacrjournals.org)
  • For example, the drug Trastuzumab targets a specific gene protein called HER2, found on the surface of some cancer cells. (fvhospital.com)
  • Patient P, a 37-year-old female patient, had developed breast cancer with a negative hormonal receptor and positive HER2 status. (fvhospital.com)
  • Dr. Bertrand also emphasises that: "Only 15 to 20 per cent of breast cancer patients are HER2 positive and are candidates for targeted therapy with the drug Trastuzumab. (fvhospital.com)
  • At Hy Vong Cancer Care Centre, all newly diagnosed breast cancers are tested for HER2 status. (fvhospital.com)
  • Any patient with HER2 positive status can be candidates for Trastuzumab treatment. (fvhospital.com)
  • Targeted therapy with Trastuzumab is a revolutionary treatment for HER2 positive breast cancer patients. (fvhospital.com)
  • Some breast cancers have high amounts of a protein called HER2 on the surface of the cancer cells (i.e. they are HER2 positive). (fvhospital.com)
  • The HER2 protein is important in promoting cancer cell growth. (fvhospital.com)
  • Trastuzumab is a specially made antibody that targets HER2-positive cancer cells. (fvhospital.com)
  • When attached to the HER2 protein, Trastuzumab can slow down or stop the growth of these cancer cells. (fvhospital.com)
  • In the N9831 trial, women with early-stage HER2-positive breast cancer received doxorubicin and cyclophosphamide followed by weekly paclitaxel (control group) or the same regimen followed by 1 year of sequential trastuzumab or concurrent trastuzumab (started on the same day as paclitaxel). (ascopost.com)
  • The current analysis of the effect of PTEN status included 1,802 of the 3,505 patients registered in N9831, with reasons for exclusion consisting of absence of HER2-positivity on central pathology review, withdrawal before starting therapy, failure to meet eligibility criteria, no consent for future translational analysis, withdrawn consent/loss to follow-up, no or inadequate tumor tissue, and technical failure. (ascopost.com)
  • Fulvestrant (Faslodex) was approved by the FDA for hormone receptor (HR)-positive, HER2-negative locally-advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy. (medscape.com)
  • Palbociclib and ribociclib are cyclin-dependent kinases (CDK) 4, 6 inhibitors indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. (medscape.com)
  • The approval of palbociclib for ER+/HER2- advanced breast cancer in combination with fulvestrant in women (regardless of menopausal status) with disease progression following endocrine therapy was based on the PALOMA-3 trial (n=521). (medscape.com)
  • Methods: From a cohort of 9982 women with surgically treated non-metastatic breast cancer, all patients with clinically reported ER-negative/borderline (≤10%) disease were selected for central assessment of ER/PR/HER2, histopathology, Ki-67, and TILs. (elsevierpure.com)
  • AstraZeneca and Merck, perceived as MSD outside the Of liking for mind Reports and Canada, today in advance ofed that Japan's Pharmaceuticals and Medical Patterns Agency (PMDA) has approved LYNPARZA ® (olaparib) covers for use in patients with unresectable or customary BRCA -mutated ( BRCA m), put forward epidermal broadening fact receptor 2 (HER2)-negative enthusiasm of hearts cancer who give birth to into the beget received until chemotherapy. (piwip.com)
  • This commend is suggestive for chest cancer patients as the estimation of BRCA variations, in furthermore to hormone receptor and HER2 repute, now grows an influential discordant with in the directing of the contagion. (piwip.com)
  • Triple-negative breast cancer is that which tests negative for three receptors: estrogen, progesterone, and human epidermal growth factor receptor 2 (HER2). (knowbreastcancer.org)
  • this may be in part because they have a higher rate of triple-negative breast cancer (negative for estrogen and progesterone receptors and human epidermal growth factor receptor [HER2] oncogene), which has a poorer prognosis than other types. (msdmanuals.com)
  • People with BRCA mutation-positive HER2‑negative high-risk early breast cancer usually have chemotherapy followed by surgery (neoadjuvant chemotherapy), or surgery followed by chemotherapy (adjuvant chemotherapy). (bvsalud.org)
  • Comutation of PIK3CA and TP53 in Residual Disease After Preoperative Anti-HER2 Therapy in ERBB2 (HER2)-Amplified Early Breast Cancer. (cdc.gov)
  • Dawson highlighted a study that followed a single patient with metastatic estrogen receptor (ER)-positive, HER2- positive breast cancer receiving two lines of targeted therapy over 3 years. (medscape.com)
  • Abstract P1-18-10: Preoperative treatment of HER2-positive breast cancer in South Sweden. (lu.se)
  • Roughly half of patients with advanced ovarian cancer have homologous recombination deficiency (HRD)-positive tumors, including those with a BRCA mutation, and one in four women have a BRCA mutation. (merck.com)
  • This phase II trial studies how well olaparib works in treating patients with bladder cancer and other genitourinary tumors with deoxyribonucleic acid (DNA)-repair defects that has spread to other places in the body (advanced or metastatic) and usually cannot be cured or controlled with treatment. (bcan.org)
  • Granotax was a prospective, open label, multicentre, national phase IV study that evaluated the incidence and severity of neutropenia in adult patients with solid tumors being treated with a docetaxel-based regimen while receiving the GCSF lenograstim. (hindawi.com)
  • They also have the very difficult and emotionally draining job of treating patients with metastatic solid tumors, for whom cure is not possible. (blogspot.com)
  • Patients with newly diagnosed metastatic triple-negative breast cancer should undergo PD-L1 expression testing on tumors to determine whether they are candidates for frontline chemoimmunotherapy. (onclive.com)
  • Patients with newly diagnosed metastatic triple-negative breast cancer (TNBC) should undergo PD-L1 expression testing on tumors to determine whether they are candidates for frontline chemoimmunotherapy, which has become the preferred standard in eligible patients, according to Kevin Kalinsky, MD, MS. (onclive.com)
  • KEYTRUDA is approved for the treatment of adult and pediatric patients with unresectable or metastatic MSI-H or dMMR solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (businesswire.com)
  • KEYNOTE-158 (ClinicalTrials.gov, NCT02628067 ) is an ongoing global, open-label, non-randomized, multi-cohort, multi-center, Phase 2 study evaluating KEYTRUDA in patients with multiple types of advanced solid tumors - including endometrial carcinoma - that have progressed on standard of care therapy. (businesswire.com)
  • Cancer Research UK's Drug Development Office has opened the first trial of a new drug combination in patients with advanced solid tumors and in a subset of patients who have non-small cell lung cancer. (med-chemist.com)
  • This trial will combine two compounds that aim to starve the tumors while simultaneously blocking cancer cell growth. (med-chemist.com)
  • Trabedersen, is an antisense compound that specifically inhibits expression of transforming growth factor beta 2 (TGF-β2) - a protein which is overexpressed in advanced tumors and which triggers key cancer pathomechanisms, i.e. suppression of antitumor immune response and metastasis. (med-chemist.com)
  • It has been said that African patients present late with aggressive tumors and face a lack of therapeutic options, resulting in short survival duration. (karger.com)
  • Of 1,802 patients, 1,342 (74%) had PTEN-positive tumors (≥ 1+ staining) and 460 (26%) had PTEN-negative tumors (0 cytoplasmic staining). (ascopost.com)
  • There were no significant differences in disease-free survival between patients with PTEN-positive vs PTEN-negative tumors defined as IHC 0 staining among all patients (hazard ratio [HR] = 0.96, P = .70) or within the control (HR = 0.92, P = .64), sequential trastuzumab (HR = 0.81, P = .27), or concurrent trastuzumab (HR = 1.40, P = .20) groups. (ascopost.com)
  • The World Health Organization (2019) classified papillary neoplasms (i.e. benign or cancerous tumors) of the breast into 5 types: intraductal papilloma, papillary ductal carcinoma in situ (PDCIS), encapsulated papillary carcinoma (EPC), solid-papillary carcinoma (SPC), and invasive papillary carcinoma (IPC). (wikipedia.org)
  • The identification of PBS tumors may require the input of breast pathologists familiar with papillary lesions of the breast. (wikipedia.org)
  • Slow growing, grade I tumors don't usually respond well to chemotherapy, so hormonal therapy is key for this type of cancer. (knowbreastcancer.org)
  • Breast cancers are most often epithelial tumors involving the ducts or lobules. (msdmanuals.com)
  • General references Breast cancers are most often epithelial tumors involving the ducts or lobules. (msdmanuals.com)
  • Conservative surgery to preserve ovarian function in patients with malignant ovarian germ cell tumors. (cancercentrum.se)
  • Surgical staging and adjuvant chemotherapy in the management of patients with adult granulosa cell tumors of the ovary. (cancercentrum.se)
  • In a recent study, researchers compared radiographic imaging of tumors with an assay of ctDNA, cancer antigen 15-3 ( CA 15-3 ), and circulating tumor cells in 30 women with MBC who were receiving systemic therapy. (medscape.com)
  • The data included in this review, from three well-conducted randomised trials, suggest that different methods of sequencing CT and RT do not appear to have a major effect on recurrence or survival for women with breast cancer if RT is commenced within seven months after surgery. (cochrane.org)
  • After surgery for localised breast cancer, radiotherapy (RT) improves both local control and breast cancer-specific survival. (cochrane.org)
  • In patients at risk of harbouring micro-metastatic disease, adjuvant chemotherapy (CT) improves 15-year survival. (cochrane.org)
  • There were no significant differences between the various methods of sequencing adjuvant therapy for local recurrence-free survival, overall survival, relapse-free survival and metastasis-free survival based on 1166 randomised women in three trials. (cochrane.org)
  • This approval was based on the OlympiAD randomised phase III trial, which showed a progression-free survival benefit for patients treated with olaparib compared to conventional chemotherapy. (wikipedia.org)
  • LYNPARZA plus bevacizumab also improved median progression-free survival (PFS) to nearly four years (46.8 months) versus 17.6 months with bevacizumab plus placebo, and 46.1% of patients who received LYNPARZA in combination with bevacizumab remain progression free versus 19.2% of patients who received bevacizumab alone. (merck.com)
  • Chemotherapy for patients with cancer of unknown primary is aimed at prolonging survival and relieving any related symptoms. (medscape.com)
  • Then, pertuzumab in 2012 and ado-trastuzumab emtansine in 2013 were approved in the US and elsewhere based on evidence showing an improvement in survival outcomes in patients with mostly trastuzumab naïve or trastuzumab-exposed metastatic disease. (carcinogenesis.com)
  • To follow patients without the pre-selected DNA-repair defects for survival. (bcan.org)
  • To correlate levels of baseline circulating tumor cells (CTCs) with survival in untreated patients. (bcan.org)
  • Demonstrate whether treatment with ruxolitinib in combination with conventional neoadjuvant and post-surgical chemotherapy results in a prolonged progression-free survival when compared to chemotherapy alone, in primary therapy for epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. (uchicagomedicine.org)
  • Investigate the prognostic significance of exploratory laboratory parameters in terms of both progression-free survival and overall survival in women receiving conventional chemotherapy alone. (uchicagomedicine.org)
  • Demonstrate whether treatment with ruxolitinib in combination with conventional chemotherapy results in an improvement in overall survival in primary management of epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. (uchicagomedicine.org)
  • Furthermore, lenograstim may increase the patient's exposure to chemotherapy allowing patients to receive optimal dosing and duration of treatment, benefitting survival. (hindawi.com)
  • Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment Factors. (curehunter.com)
  • Cancers for which adjuvant chemotherapy has been shown to improve survival and disease-free survival include breast cancer, colorectal cancer, and several others. (blogspot.com)
  • The primary efficacy outcome was progression-free survival (PFS) as assessed by blinded independent central review, with a median PFS of 7.0 months in the olaparib arm, and 4.2 months in the chemotherapy arm, resulting in a hazard ratio of 0.58. (fda.gov)
  • The median progression-free survival (PFS) for patients treated with trastuzumab deruxtecan was not reached (95% CI: 18.5-NE) compared to 6.8 months for T-DM1 (95% CI: 5.6-8.2) as assessed by blinded independent central review (BICR). (tt.se)
  • TNBC is an aggressive cancer with a high recurrence rate and a low five-year survival rate compared to other cancer types. (pharmaphorum.com)
  • Given the high risk of recurrence, new treatment options for use in the earlier stages of the cancer pathway are needed to improve survival rates and provide more positive treatment outcomes for patients. (pharmaphorum.com)
  • There is progress being made in the treatment of lung cancer but survival rates still remain low. (med-chemist.com)
  • We hope that this new approach may eventually contribute to increased survival for lung cancer patients. (med-chemist.com)
  • Conclusion: Re-resection for breast cancer liver metastases can be safely performed and may bring survival benefit. (iiarjournals.org)
  • However, during the last few decades the overall survival rates significantly increased even in cases presenting recurrent disease: in a cohort study conducted at the MD Anderson Cancer Center between 1974 and 2000 involving patients with recurrent breast cancer, the median survival rate improved from 15 months to 58 months over the last decades ( 2 ). (iiarjournals.org)
  • The median survival of patients with metastatic breast cancer is 18 to 24 months, although the range in survival spans between a few months and many years and often depends on the pattern or burden of metastatic spread. (biomedcentral.com)
  • Determine time to progression and overall survival of these patients receiving this regimen. (knowcancer.com)
  • Patents receiving trastuzumab had significantly better disease-free survival and overall survival compared with the control group, and patients receiving concurrent trastuzumab had significantly better disease-free survival than those receiving sequential trastuzumab. (ascopost.com)
  • When PTEN-negativity was defined as IHC 0-1 staining, there were no significant differences in disease-free survival for PTEN-positive vs PTEN-negative patients among all patients (HR = 0.96, P = .70) or within the control (HR = 0.87, P = .38), sequential trastuzumab (HR = 0.79, P = .19), or concurrent trastuzumab (HR = 1.27, P = .25) groups. (ascopost.com)
  • To compare the progression free survival (PFS) of patients treated with nab-paclitaxel + placebo and patients treated with nab-paclitaxel + mifepristone. (uchicagomedicine.org)
  • Determine the overall survival and progression-free survival of patients treated with this drug. (knowcancer.com)
  • The combination of adjuvant chemotherapy and endocrine therapy is no more effective than endocrine therapy alone in improving survival outcomes in patients with early-stage invasive lobular breast cancer, Cleveland Clinic investigators have found. (knowbreastcancer.org)
  • Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance). (cdc.gov)
  • Some factors such as individual treatment strategy, according to the histology of the primary tumor, plan of treatment strategies carried out in a multidisciplinary manner, risk-benefit of radiotherapy, assessment of the degree of spinal instability, improvement in communication and referral between specialists in oncology showed an increase in the survival of these patients. (bvsalud.org)
  • These findings are important for cancer treatment planning and help professionals to seek greater survival. (bvsalud.org)
  • R, Flisberg P, Hedlund L, Östlund I, Bergkvist L. Impact of general anaesthesia on breast cancer survival: a 5-year follow up of a pragmatic, randomised, controlled trial, the CAN-study, comparing propofol and sevoflurane. (cancercentrum.se)
  • Associations of a Breast Cancer Polygenic Risk Score With Tumor Characteristics and Survival. (cancercentrum.se)
  • If patients have hormone receptor positive cancer, they should have received endocrine therapy where appropriate. (wikipedia.org)
  • These include: Patients with hormone receptor-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. (fda.gov)
  • Broadly speaking, for patients with HER-2 negative metastatic breast cancers expressing hormone receptors, systemic treatment begins with endocrine therapy such as tamoxifen, until hormones are no longer effective. (fda.gov)
  • Clinicians may pursue more aggressive therapy immediately (e.g. chemotherapy instead of endocrine therapy) in patients with bone metastasis who are at high likelihood of imminent visceral metastasis, or similarly add bone-directed therapy in patients with visceral metastasis who are at high likelihood of imminent bone metastasis. (biomedcentral.com)
  • Eligible patients had received no prior endocrine therapy, although treatment with 1 prior chemotherapy. (medscape.com)
  • Treatment usually includes surgical excision, often with radiation therapy, and with or without adjuvant chemotherapy, endocrine therapy, or both. (msdmanuals.com)
  • In August 2017, olaparib tablets were approved in the United States for the maintenance treatment of adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy. (wikipedia.org)
  • The Phase 3 PAOLA-1 trial evaluated LYNPARZA in combination with bevacizumab as first-line maintenance therapy in patients with advanced ovarian cancer, who were without evidence of disease after surgery or following response to platinum-based chemotherapy. (merck.com)
  • Treatments that include platinum-based chemotherapy are used in patients with squamous cell carcinoma. (medscape.com)
  • Patients were stratified by prior chemotherapy use in the metastatic setting, hormone receptor-positive vs. triple-negative, and prior use of platinum-based chemotherapy. (fda.gov)
  • In July 2021, the FDA granted regular approval to pembrolizumab (Keytruda), a PD-1 inhibitor, in combination with chemotherapy for patients with unresectable or metastatic TNBC with PD-L1 positivity, defined as a combined positive score (CPS) of 10 or greater via an FDA-approved test. (onclive.com)
  • In the metastatic setting, the phase 3 KEYNOTE-355 (NCT02819518) trial evaluated pembrolizumab plus chemotherapy in patients with locally recurrent unresectable or metastatic TNBC who had not previously received chemotherapy in the metastatic setting, regardless of PD-L1 expression status. (onclive.com)
  • 2 At the same time, the FDA approved pembrolizumab for patients with high-risk, early-stage TNBC in combination with chemotherapy as neoadjuvant treatment and then continued as a single agent as adjuvant treatment after surgery. (onclive.com)
  • NICE's decision was based on results from the randomised, double-blind, placebo-controlled KEYNOTE-522 trial, which evaluated the efficacy of pembrolizumab in combination with chemotherapy in 1,174 patients with newly diagnosed, previously untreated and non-metastatic TNBC. (pharmaphorum.com)
  • After a median follow-up of 39.1 months, pembrolizumab, in combination with chemotherapy, led to a statistically significant and clinically meaningful improvement in EFS compared with chemotherapy alone. (pharmaphorum.com)
  • The evidence produced by these three well-conducted trials suggests that recurrence of a woman's cancer and her chances of dying from breast cancer are similar regardless of the order of the treatments, provided that both radiotherapy and chemotherapy are commenced within seven months of the surgery. (cochrane.org)
  • They also administer adjuvant chemotherapy, which is chemotherapy given after surgery with curative intent that is designed to decrease the rate of recurrence. (blogspot.com)
  • The National Institute for Health and Care Excellence (NICE) has recommended the use of KEYTRUDA (pembrolizumab) as an option with chemotherapy for neoadjuvant, and alone as adjuvant treatment after surgery, for adults with early TNBC, at high risk of recurrence, or locally advanced TNBC. (pharmaphorum.com)
  • Even in cases in which surgical treatment can provide a complete resection, liver recurrence is not a rare event, being reported in up to half of patients initially submitted to liver resection ( 8 ). (iiarjournals.org)
  • In order to be considered eligible for the study, the patients had to meet the following criteria: histopathological confirmation of breast cancer liver metastases diagnosis at the moment of primary liver resection and re-submission to surgery for preoperative diagnosis of hepatic recurrence. (iiarjournals.org)
  • Treatment is aimed at reducing the risk of future recurrence, thereby reducing breast cancer−related morbidity and mortality. (medscape.com)
  • Background: Given its high recurrence risk, guidelines recommend systemic therapy for most patients with early-stage triple-negative breast cancer (TNBC). (elsevierpure.com)
  • Possible mechanisms for gram for breast cancer in southern Sweden issued 1991, pre- recurrence after treatment are low initial drug sensitivity or menopausal lymph node positive (N+) breast cancer patients an acquired drug resistance. (lu.se)
  • However, perhaps the most important additional skills and knowledge provided by a surgical oncology fellowship are the understanding of the multidisciplinary management of the major cancers that are primarily treated with surgery, such as breast cancer, colorectal cancer, melanoma, stomach cancer, pancreatic cancer, and liver cancer. (blogspot.com)
  • Cost-utility analysis and cross-country comparison of pharmacogenomics-guided treatment in colorectal cancer patients participating in the U-PGx PREPARE study. (cdc.gov)
  • If they are used sequentially, the radiotherapy or the chemotherapy could be used first and concerns have been expressed that the effectiveness of the therapy that is delayed might be reduced. (cochrane.org)
  • However, the best sequence of administering these two types of adjuvant therapy for early-stage breast cancer is unclear. (cochrane.org)
  • The approval in the maintenance setting was based on two randomized, placebo-controlled, double-blind, multicenter trials in patients with recurrent ovarian cancers who were in response to platinum-based therapy. (wikipedia.org)
  • Patients in whom combination therapy fails may benefit from single-agent treatment with gemcitabine, with median time to progression of 5 months. (medscape.com)
  • Gemcitabine HCI for Injection is indicated in combination with Carboplatin for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy as well as in combination with Cisplatin for the first-line treatment of patients with inoperable, locally advanced (stage IIIA or IIIB), or metastatic (stage IV) non-small cell lung cancer. (fresenius-kabi.com)
  • I. Determine whether treatment with ruxolitinib phosphate (ruxolitinib) in combination with conventional neoadjuvant and post-surgical chemotherapy is safe and tolerable in the primary therapy for epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. (uchicagomedicine.org)
  • I. Determine frequency of patients who do not receive surgery within 6 weeks of completing cycle 3 therapy for reasons other than non-response, disease progression, or medical contraindications. (uchicagomedicine.org)
  • Determine if continuation of ruxolitinib as maintenance therapy in participants who complete 6 cycles of standard chemotherapy in combination with ruxolitinib and have not experienced unacceptable toxicity or disease progression is safe and tolerable. (uchicagomedicine.org)
  • Local Therapy Decision-Making and Contralateral Prophylactic Mastectomy in Young Women with Early-Stage Breast Cancer. (curehunter.com)
  • Radiation oncologists sometimes are the primary treatment for some cancers with or without chemotherapy (Hodgkin's lymphoma, anal cancer, for example), but most of the time they give adjuvant therapy after surgery, as in breast cancer and rectal cancer. (blogspot.com)
  • The emergence of immune checkpoint inhibitor (ICI) therapy for patients with PD-L1-positive TNBC is among the advancements in the past several years that are shaping the treatment landscape for this breast cancer subtype. (onclive.com)
  • Furthermore, patients should receive genetic testing to assess whether they are candidates for PARP inhibitor therapy or for a treatment approach associated with germline aberrations. (onclive.com)
  • Pembrolizumab therapy also resulted in a 52.7% objective response rate ([ORR] 95% CI, 45.9%-59.5%) in patients with a CPS of 10 or greater compared with 40.8% (95% CI, 31.2%-50.9%) with placebo. (onclive.com)
  • The regular approval for pembrolizumab in metastatic TNBC converted an accelerated approval that the FDA had granted for the agent in November 2020 and solidified a place for ICI therapy in the treatment paradigm for this breast cancer subtype. (onclive.com)
  • inclusion criteria were hormone receptor positivity, no metastatic disease at diagnosis, adjuvant tamoxifen therapy, and no chemotherapy. (elsevierpure.com)
  • KEYTRUDA was also granted accelerated approval in September 2019, and received full approval in July 2021, in combination with LENVIMA ® (lenvatinib) for the treatment of patients with advanced endometrial carcinoma that is not MSI-H or dMMR, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. (businesswire.com)
  • 2 cm in diameter, as adjuvant therapy following neoadjuvant chemotherapy and surgery (see sections 4.4 and 5.1). (who.int)
  • The primary objective was to compare the number of patients who achieved a pathological complete response (ypT0/is, ypN0), between groups in the intention-to-treat population (two-sided assessment), based on local evaluation of tumour samples taken at breast cancer surgery done between 14 days and 6 weeks after completion of neoadjuvant therapy. (nih.gov)
  • MRK ), known as MSD outside of the United States and Canada, and Eisai today provided updates on two Phase 3 trials, LEAP-006 and LEAP-008, evaluating KEYTRUDA, Merck's anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, in patients with certain types of metastatic non-small cell lung cancer. (streetinsider.com)
  • The major cause of mortality from breast cancer is metastatic relapse, which can occur despite intensive adjuvant therapy at the time of diagnosis. (grantome.com)
  • Utilisation of targeted therapy in adjuvant treatment or metastatic breast cancer was approved by the USA Food and Drug Administration (FDA). (fvhospital.com)
  • Together with other advanced cancer treatments offered at Hy Vong Cancer Care Centre, FV Hospital, targeted therapy creates more opportunities for successful treatment. (fvhospital.com)
  • Targeted therapy is highly rated by oncologists and considered a "weapon" for adjuvant treatment in advanced-stage breast cancers. (fvhospital.com)
  • Dr. Bertrand Farnault , Head of Hy Vong Cancer Care Centre, says, Targeted therapy is very efficient and was very well tolerated in case of patient P. The patient did not have any complications during the whole treatment process. (fvhospital.com)
  • At Hy Vong Cancer Care Centre, we have provided this targeted therapy to many patients in this group. (fvhospital.com)
  • No prior nab-paclitaxel or mifepristone therapy for metastatic disease will be allowed. (uchicagomedicine.org)
  • Patients with HER-2-directed therapy, metastatic disease, second primary malignancy or pre-existing cardiovascular disease were excluded from the analyses as were patients with LVEF decline for reasons other than anthracycline-induced cardiotoxicity. (bvsalud.org)
  • Adjuvant treatment for breast cancer involves radiation therapy and a variety of chemotherapeutic and biologic agents. (medscape.com)
  • In patients receiving adjuvant aromatase inhibitor therapy for breast cancer who are at high risk for fracture, the monoclonal antibody denosumab or either of the bisphosphonates zoledronic acid and pamidronate may be added to the treatment regimen to increase bone mass. (medscape.com)
  • Bevacizumab, a humanized monoclonal antibody that inhibits angiogenesis, had been approved for use in combination therapy for metastatic breast cancer. (medscape.com)
  • Approval of ribociclib was based on interim analysis results from the pivotal phase 3 MONALEESA-2 trial in postmenopausal women who received no prior systemic therapy for their advanced breast cancer. (medscape.com)
  • Patients were stylish for therapy faked upon a substantiated BRCA transfiguration. (piwip.com)
  • Treatment often consists of surgery and additional (adjuvant) therapy, which may include chemotherapy , radiation and hormone therapy. (knowbreastcancer.org)
  • Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU Chemotherapy. (cdc.gov)
  • Radiotherapy was delivered to ipsilateral axil- cancer patients in the future, it is essential to increase our lary and supraclavicular lymph nodes and the remaining knowledge in mechanisms responsible for drug resistance, breast parenchyma after breast conservation surgery or tho- and to define reliable indicators for response to therapy. (lu.se)
  • Assess the antitumor activity of pemetrexed disodium in combination with gemcitabine in the treatment of women with metastatic breast cancer who have received an anthracycline and a taxane in the adjuvant and/or metastatic setting and no more than 1 chemotherapy regimen for metastatic disease (unless these were a taxane and anthracycline). (knowcancer.com)
  • SOLO-2 (NCT01874353) randomized 295 patients with recurrent germline BRCA-mutated ovarian, fallopian tube, or primary peritoneal cancer (2:1) to receive olaparib tablets 300 mg orally twice daily or placebo. (wikipedia.org)
  • Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance). (curehunter.com)
  • Moreover, in October, Scotland became the first country in the UK to back NHS funding for the use of Merck & Co/MSD's Keytruda in combination with Eisai's Lenvima as a treatment for advanced or recurrent endometrial cancer. (pharmaphorum.com)
  • Exclusion criteria included age below 18 years at the time of diagnosis, presentation with a diagnosis and or treatment of recurrent disease within 5 years of primary and second primary cancers, and initial referral for diagnosis or palliative treatment of advanced unresectable/metastatic cancer. (ajmc.com)
  • The main inclusion criteria were presence of isolated liver metastases and absence of systemic recurrent disease Results: The median age at the time of breast surgery was 51 years (range=39-69 years). (iiarjournals.org)
  • Our studies will define key signals from the host tissue that allow BCCs to persist in metastatic sites, allowing us to design new, minimally toxic strategies to eradicate the source of recurrent disease. (grantome.com)
  • 5. Patients may have received adjuvant chemotherapy and up to two prior chemotherapy for metastatic or locally recurrent disease. (uchicagomedicine.org)
  • In patients with breast cancer and imaging findings suggestive of skeletal metastases, it is important to keep a broad differential diagnosis and consider bone biopsy for a definitive diagnosis. (cmaj.ca)
  • Dates of histopathologic diagnosis were obtained from the Montefiore cancer registry and billing data were used to determine treatment dates. (ajmc.com)
  • age at initial diagnosis of breast cancer, histopathological result, age at diagnosis of the first and second liver resection, type of resection, number and diameter of the lesions, type of resection at both primary and secondary liver surgery, association of neo-adjuvant and adjuvant oncologic treatment at each moment including breast surgery, first and second liver resection. (iiarjournals.org)
  • Metastases from primary breast cancers can involve single or multiple organs at metastatic disease diagnosis. (biomedcentral.com)
  • Identification of these patients at an early stage after primary diagnosis or during early metastatic disease is not well-established. (biomedcentral.com)
  • are actually present at the time of diagnosis in many patients. (grantome.com)
  • Assessment tools for risk prediction of breast cancer are also highlighted as chapters run the gamut of current imaging modalities, as well as advanced screening options available for diagnosis and following these patients. (nshealth.ca)
  • Lobular breast cancer can recur and metastasize many years after diagnosis and treatment , so it is important to be aware of metastatic symptoms. (knowbreastcancer.org)
  • In cancer, a person is considered to be a survivor from the time of diagnosis until the end of life . (knowbreastcancer.org)
  • In an exploratory subgroup analysis of HRD-positive patients, LYNPARZA plus bevacizumab provided a clinically meaningful improvement in OS, reducing the risk of death by 38% (HR=0.62 [95% CI, 0.45-0.85]) versus bevacizumab alone. (merck.com)
  • Gemcitabine HCI for Injection is also indicated in combination with Paclitaxel for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. (fresenius-kabi.com)
  • Bone marrow (BM) biopsies performed on women with early stage breast cancer have shown that small, clinically unapparent ?micrometastases? (grantome.com)
  • Now in a single, convenient volume, The Breast: Comprehensive Management of Benign and Malignant Diseases, 5th Edition covers every clinically relevant aspect of the field: cancer, congenital abnormalities, hormones, reconstruction, anatomy and physiology, benign breast disease, and more. (nshealth.ca)
  • They are a clinically, histologically, and biologically heterogeneous group of breast cancers that are often difficult to distinguish from each other as well as from other papillary breast lesions. (wikipedia.org)
  • Osseous sarcoidosis is an uncommon manifestation of sarcoidosis that can mimic metastatic bone disease on imaging. (cmaj.ca)
  • More than two-thirds of patients with ovarian cancer are diagnosed with advanced disease, and approximately 50-70% of these patients die within five years. (merck.com)
  • When patients are newly diagnosed with metastatic disease, they should have testing," he said. (onclive.com)
  • All patients must have had prior chemotherapy, as adjuvant, neoadjuvant, or for metastatic disease. (fda.gov)
  • If approved by the European Commission, patients in Europe may be able to benefit from this important medicine earlier in the treatment of their disease, improving their chance for better outcomes. (tt.se)
  • In the U.S., it is estimated there will be more than 66,000 new cases of uterine body cancer and nearly 13,000 deaths from the disease in 2021. (businesswire.com)
  • Chief investigator, Dr. Denis Talbot, consultant medical oncologist at Oxford University Hospitals NHS Trust and Cancer Research UK clinician at The University of Oxford, said: "Therapies for lung cancer often become ineffective because the disease becomes resistant to treatment, so we're delighted to launch this trial to test a new approach that we hope will help people with this common disease. (med-chemist.com)
  • however, some patients remain at risk of relapse or death for many years after treatment of early-stage disease. (nih.gov)
  • While these results are not what we hoped for, we are proud of the foundational role that KEYTRUDA has established in the treatment of certain types of lung cancer, and we are committed to continuing to research how we can further improve responses to our medicines for patients with difficult-to-treat forms of the disease. (streetinsider.com)
  • Breast cancer remains an important health problem worldwide with an estimated incidence of 207,090 cases in the United States in 2010 and a mortality rate related to metastatic disease of 39,840 cases in the same year ( 1 ). (iiarjournals.org)
  • Among patients with liver-confined metastatic disease only 10% of them will be eligible for liver resection ( 4 ). (iiarjournals.org)
  • Moreover, a novel gene module was identified as a putative risk factor for metasynchronous bone and visceral first metastatic spread, with potential implications for disease monitoring and treatment planning. (biomedcentral.com)
  • Most clinicians recommend initial treatment with chemotherapy for rapidly progressive visceral disease or in women with severe symptoms related to metastatic breast cancer [ 5 ]. (biomedcentral.com)
  • These micrometastases can survive in the face of adjuvant chemotherapy and lay dormant for years before they become proliferative, causing overt metastatic disease. (grantome.com)
  • 1. Patients must have histologically or cytologically confirmed breast cancer with stage IV or unresectable stage III disease. (uchicagomedicine.org)
  • Atypical Breast Proliferative Lesions and Benign Breast Disease will undoubtedly become a valuable resource for nurse practitioners, physician assistants, breast and surgical oncology fellows, genetic counselors, geneticists, as well as other clinicians and surgeons who are referred and manage these complex breast patients. (nshealth.ca)
  • It is designed to treat micrometastatic disease (or breast cancer cells that have escaped the breast and regional lymph nodes but which have not yet had an established identifiable metastasis). (medscape.com)
  • In December 2013, Hoffmann-La Roche, manufacturer of capecitabine (Xeloda), an oral agent for the treatment of breast and colorectal cancers, reported that in rare cases, patients using the drug may develop potentially fatal cutaneous disease, such as Stevens-Johnson syndrome or toxic epidermal necrolysis. (medscape.com)
  • The spine is the most frequent area of bone metastasis in patients with systemic neoplastic disease. (bvsalud.org)
  • Nonetheless, loss, constipation and diarrhoea) and fi- most patients with operable disease have nancial difficulties. (who.int)
  • In patients with advanced disease, it's impossible to biopsy every single site of the disease," she said at the San Antonio Breast Cancer Symposium (SABCS) last December. (medscape.com)
  • A 49-year-old premenopausal woman underwent lumpectomy and sentinel lymph node biopsy for grade 1 invasive ductal carcinoma of the right breast. (cmaj.ca)
  • Delayed technetium 99m-methyl diphosphonate (99mTc-MDP) whole-body skeletal scans in a 49-year-old woman with ductal carcinoma of the right breast. (cmaj.ca)
  • Breast disorders occurring in pediatric patients range from congenital conditions to neonatal infections and from benign disorders such as fibroadenoma in females and gynecomastia in males to breast carcinoma and rhabdomyosarcoma . (medscape.com)
  • KEYTRUDA monotherapy is already playing a role for the treatment of certain patients with advanced endometrial carcinoma through the tumor-agnostic MSI-H indication which received accelerated approval four years ago. (businesswire.com)
  • Cohort K enrolled 79 patients with MSI-H endometrial carcinoma and Cohort D enrolled 11 patients with MSI-H endometrial carcinoma for a total of 90 pooled patients who received KEYTRUDA as monotherapy (200 mg fixed dose every three weeks). (businesswire.com)
  • Endometrial carcinoma begins in the inner lining of the uterus, which is known as the endometrium, and is the most common type of cancer in the uterus. (businesswire.com)
  • more than 90% of uterine body cancers occur in the endometrium, so the actual numbers for endometrial carcinoma cases and deaths are slightly lower than these estimates). (businesswire.com)
  • Lobular Carcinoma In Situ: Risk Factor or Cancer Precursor? (nshealth.ca)
  • Ductal Carcinoma In Situ: Risk Factor or Cancer -- Diagnostic Management of Papillomas, Radial Scars, and Flat Epithelial Atypia: Core Biopsy Alone Versus Core Biopsy Plus Excision -- Diagnostic Management of Fibroepithelial Lesions: When Is Excision Indicated? (nshealth.ca)
  • Your treatment options for invasive lobular carcinoma depend on the aggressiveness of your cancer, its stage, your overall health and your preferences. (knowbreastcancer.org)
  • Doctors know that invasive lobular carcinoma begins when cells in one or more milk-producing glands of the breast develop mutations in their DNA. (knowbreastcancer.org)
  • The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced updated results from a phase 2 study of orteronel , a selective oral 17,20 lyase inhibitor, dosed without prednisone in patients with non-metastatic castration resistant prostate cancer (nmCRPC) and rising prostate-specific antigen. (med-chemist.com)
  • To explore tumor-mutational profiles in metastatic tumor biopsies, saliva "normal" DNA, changes in tumor or peripheral immune characteristics, or tumor associated somatic mutation load in blood DNA in response to treatment. (bcan.org)
  • To determine the effectiveness of using next-generation sequencing (NGS) to identify DNA-repair pathway gene defects in tumor samples and circulating DNA and identify patients with non-prostate GU cancer suitable for PARP inhibition. (bcan.org)
  • Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. (uchicagomedicine.org)
  • Within 6 weeks after completion of cycle 3, patients undergo tumor reductive surgery (TRS). (uchicagomedicine.org)
  • In the first stage patients with any solid tumor will each receive a drug called vandetanib (below left) and an investigational drug called selumetinib (right structure below)AZD6244, ARRY142886). (med-chemist.com)
  • 1. To correlate percentage glucocorticoid receptor (GR) positivity in the most recent metastatic tumor biopsy (or in primary tumor if only primary tumor is available) with PFS in mifepristone and placebo groups. (uchicagomedicine.org)
  • While some clinicopathologic factors and tumor-infiltrating lymphocytes (TILs) are known to be prognostic in patients receiving chemotherapy, their prognostic implications in systemically untreated patients remain unknown. (elsevierpure.com)
  • This suggests that breast-conserving surgery leads to similar outcomes despite tumor histology. (knowbreastcancer.org)
  • The cancer may come back to the same place as the original primary tumor or to another place in the body. (knowbreastcancer.org)
  • Ovarian granulosa cell tumor and increased risk of breast cancer. (cancercentrum.se)
  • In the past 5 years, there has been an explosion of breast cancer research on circulating tumor DNA (ctDNA), fueled by the idea that ctDNA may provide a liquid biopsy alternative to tissue biopsies. (medscape.com)
  • Changes in levels of circulating tumor DNA very closely followed treatment responses in these patients, and tracking levels of ctDNA may provide us with an early indicator of treatment resistance," said Dawson. (medscape.com)
  • [1] Although chemotherapy has improved outcomes for patients, the marginal benefits achieved with cytotoxic agents seem to have reached a plateau. (carcinogenesis.com)
  • BT-ON013 trade name] treatment should only be initiated by a health care provider experienced in the administration of cytotoxic chemotherapy (see section 4.4), and should be administered by a health care provider only. (who.int)
  • Depending on each large tumours and/or histologically proven patient's education level, the questionnaire axillary lymph node involvement requiring was either self-completed or administered adjuvant cytotoxic chemotherapy. (who.int)
  • Among the 394 enrolled patients the incidence of grade 3-4 neutropenia was 16.2% and of febrile neutropenia was 1.5%, far lower than the reported 85-100% and 30-40% incidence without G-CSFs. (hindawi.com)
  • The low incidence of adverse effects and chemotherapy dose changes, delays, and withdrawals supports the use of lenograstim as effective primary prophylaxis in South African patients being treated with a docetaxel-based regimen. (hindawi.com)
  • Pneumocystis jiroveci pneumonia (PCP) in patients receiving neoadjuvant and adjuvant anthracycline-based chemotherapy for breast cancer: incidence and risk factors. (curehunter.com)
  • The global incidence of breast cancer (BC) is rising, especially in low- and middle-income countries. (karger.com)
  • BC has the highest incidence rate of all cancers in women worldwide (1.67 million) and accounts for over 500,000 deaths annually [ 2 ]. (karger.com)
  • Although can- number of positive axillary lymph nodes cer incidence is increasing in the developing and chemotherapy regimen. (who.int)
  • In the USA, obesity has recent- obesity is associated with progres- aberrations of cancer cells, summa- ly surpassed tobacco use as the sion but not incidence [9]. (who.int)
  • In addition, obesity is associated with progression (but not incidence) of tumour microenvironment through prostate cancer. (who.int)
  • We are in Silver Spring, MD, and during our soundcasts, we discuss recent FDA approvals of cancer drugs and therapies. (fda.gov)
  • We hope this information will help you to better understand these approvals and how new drugs and therapies are benefitting cancer patients. (fda.gov)
  • Emerging Adjuvant Therapies: What's Ready for Prime Time? (nursingcenter.com)
  • Unlike chemotherapy drugs, targeted therapies kill cancer cells with little harm to healthy cells. (fvhospital.com)
  • One of the drawbacks of these therapies is that they only work on cancers that have the specific markers which they were designed to target. (fvhospital.com)
  • Therefore, not all patients are candidates for these therapies. (fvhospital.com)
  • He spent two years at the National Institutes of Health as a surgical oncology fellow at the National Cancer Institute, where his research focused on immune-based therapies for melanoma. (learnhowtospeedread.org)
  • Pelvic lymphadenectomy provides prognostic information for those diagnosed with endometrial (womb) cancer and provides information that may influence decisions regarding adjuvant treatment. (essentialevidenceplus.com)
  • p=0.4118) in patients with newly diagnosed advanced ovarian cancer. (merck.com)
  • I. To evaluate the efficacy of olaparib in two cohorts of patients with metastatic/advanced non prostate genitourinary (GU) cancer pre-selected by DNA-repair defects as measured by overall response rate (ORR). (bcan.org)
  • Furthermore, they can lead to delays and dose reductions in chemotherapy treatment, thereby potentially compromising the efficacy of chemotherapy and, consequently, patient outcome [ 10 ]. (hindawi.com)
  • This accelerated approval was based on efficacy data from patients enrolled in one of five open-label, multi-cohort trials, including KEYNOTE-158. (businesswire.com)
  • Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatments: The M77001 Study Group. (roche.com)
  • Feedback indicated that eRAPID has the potential to improve patients' self-efficacy, knowledge and confidence with managing symptoms during treatment. (bmj.com)
  • Phase II) V. Determine whether treatment with ruxolitinib in combination with conventional chemotherapy is associated with total gross resection rate at time of interval cytoreductive surgery. (uchicagomedicine.org)
  • Determine whether treatment with ruxolitinib in combination with conventional chemotherapy is associated with complete pathologic response defined at interval cytoreductive surgery. (uchicagomedicine.org)
  • Between June 25, 2014, and June 15, 2015, we randomly assigned 444 patients to neoadjuvant treatment with trastuzumab emtansine plus pertuzumab (n=223) or docetaxel, carboplatin, and trastuzumab plus pertuzumab (n=221). (nih.gov)
  • Clinic pathologic characteristics and outcomes in the 1,802 patients from the three treatment groups included in the analysis (601 in control group, 650 in sequential trastuzumab group, and 551 in concurrent trastuzumab group) were similar to excluded patients in the three treatment groups. (ascopost.com)
  • Olaparib, sold under the brand name Lynparza, is a medication for the maintenance treatment of BRCA-mutated advanced ovarian cancer in adults. (wikipedia.org)
  • It acts against cancers in people with hereditary BRCA1 or BRCA2 mutations, which include some ovarian, breast, and prostate cancers. (wikipedia.org)
  • The FDA approval is in germline BRCA mutated (gBRCAm) advanced ovarian cancer that has received three or more prior lines of chemotherapy. (wikipedia.org)
  • RAHWAY, N.J.--(BUSINESS WIRE)-- AstraZeneca and Merck, known as MSD outside of the United States and Canada, today announced long-term follow-up results from the Phase 3 PAOLA-1 and SOLO-1 trials in first-line advanced ovarian cancer, which represent the longest-term data for any PARP inhibitor in this setting. (merck.com)
  • This phase I/II trial studies the side effects and the best dose of ruxolitinib phosphate when given together with paclitaxel and carboplatin and to see how well they work in treating patients with stage III-IV epithelial ovarian, fallopian tube, or primary peritoneal cancer. (uchicagomedicine.org)
  • Giving ruxolitinib phosphate together with paclitaxel and carboplatin may be a better treatment for epithelial ovarian, fallopian tube, or primary peritoneal cancer compared to paclitaxel and carboplatin alone. (uchicagomedicine.org)
  • Three PARP inhibitors already have approval for use in various settings for women with ovarian cancer, as we've discussed at the DISCO previously. (fda.gov)
  • Dave Fredrickson, chief governmental vice president, activate of the oncology announcement unit at AstraZeneca, asseverated, "Earlier this year, LYNPARZA changed the head PARP inhibitor available in Japan for promoted ovarian cancer. (piwip.com)
  • LYNPARZA is also approved in Japan as credit treatment for charwomen with platinum-sensitive relapsed ovarian cancer, regardless of BRCA transforming status. (piwip.com)
  • Sieh W, Sundquist K, Sundquist J, Winkleby MA, Crump C. Intrauterine factors and risk of nonepithelial ovarian cancers. (cancercentrum.se)
  • Prior chemotherapy must have included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. (who.int)
  • To determine the effects of different sequencing of adjuvant CT and RT for women with early breast cancer. (cochrane.org)
  • In February 1998 she joined the CRCTU as a Trial Coordinator coordinating a national, multicentre, phase III, trial called SECRAB which was designed to determine the optimal sequence of chemotherapy and radiotherapy in patients with early breast cancer. (birmingham.ac.uk)
  • Participants 12 patients receiving chemotherapy for early breast cancer and 10 health professionals (oncologists and specialist nurses). (bmj.com)
  • To assess the feasibility of QOL assessment in a cohort of Tunisian cancer patients, the EORTC QLQ-C30 questionnaire was administered to 23 women treated with adjuvant chemotherapy for early breast cancer on an outpatient basis at baseline and during the 3rd cycle of chemotherapy. (who.int)
  • Patients experienced median TTIs of 35 days (IQR, 12.5-51) for breast cancer, 16 days (IQR, 6-40) for CRC, 32 days (IQR, 15-45) for HNC, 20 days (IQR, 7-39) for NSCLC, and 15.5 days (IQR, 5-29) for pancreatic cancer. (ajmc.com)
  • I. To determine the proportion of patients with DNA-repair pathway-mutated genes in metastatic non-prostate GU cancer (patient cohort referred for screening). (bcan.org)
  • COHORT I: Patients that have cancer-associated DNA-repair gene mutations receive olaparib orally (PO) twice daily (BID) on days 1-28 of each cycle. (bcan.org)
  • COHORT II: Patients that do not have cancer-associated DNA-repair gene mutations undergo blood sample collection at baseline. (bcan.org)
  • Molecular Phenotype of Breast Cancer According to Time Since Last Pregnancy in a Large Cohort of Young Women. (curehunter.com)
  • BV was further orthogonally validated with NanoString nCounter in primary breast cancers, and was reproducible in their matched lymph nodes metastases and an external cohort. (biomedcentral.com)
  • METHODS: Single center consecutive cohort study of all breast cancer patients with ECG and transthoracic echocardiography (TTE) evaluation before and after (neo)adjuvant anthracycline chemotherapy. (bvsalud.org)
  • METHODS: The PCE was validated in a community-based cohort of consecutive patients who sought primary care in Olmsted County, Minnesota, between 1997 and 2000, followed-up through 2016. (bvsalud.org)
  • assess the feasibility of QOL evaluation in a The QLQ-C30 was assessed by the same cohort of Tunisian women with early breast physician (A.M.) at 2 points of time: just cancer receiving adjuvant chemotherapy. (who.int)
  • Inflammatory Drugs and Risk of Breast Cancer: Evidence from a General Female Population and a Mammographic Screening Cohort in Sweden. (cancercentrum.se)
  • Johnsson A, Kiani NA, Gernaat SAM, Wilking U, Shabo I, Hedayati E. Planning for return to work during the first year after breast cancer metastasis: A Swedish cohort study. (cancercentrum.se)
  • Schiza A, Fredriksson I, Sund M, Valachis A. De novo metastatic breast cancer in men vs women: a Swedish population-based cohort study. (cancercentrum.se)
  • Two of these, with 853 women, assessed radiotherapy and chemotherapy given at the same time versus chemotherapy given first followed by radiotherapy. (cochrane.org)
  • The third trial randomised 244 women to radiotherapy followed by chemotherapy versus chemotherapy followed by radiotherapy. (cochrane.org)
  • 65.5% of patients who received LYNPARZA plus bevacizumab were still alive at five years versus 48.4% who received bevacizumab alone. (merck.com)
  • At the seven-year descriptive OS analysis, 67% of LYNPARZA patients were alive versus 47% of placebo patients (44% of whom had a subsequent PARP inhibitor), and 45% of LYNPARZA patients versus 21% of placebo patients were alive and had not received a first subsequent treatment. (merck.com)
  • The credentials is based on basis from the randomized, open-label, Perspective 3 OlympiAD disquiet, which probed LYNPARZA versus chemotherapy. (piwip.com)
  • Median PFS was 7.0 months with LYNPARZA versus 4.2 months with chemotherapy. (piwip.com)
  • Medical and surgical postoperative complications after breast conservation versus mastectomy in older women with breast cancer: Swedish population-based register study of 34 139 women. (cancercentrum.se)
  • 001) and a higher rate of nodal positivity (87% vs 83%, P = .04) compared with PTEN-negative patients. (ascopost.com)
  • The study was carried out to exhaust the scientific literature regarding surgery associated with radiotherapy in patients suffering from metastatic spinal cord compression and to assist in the decision of oncology physicians and professionals in choosing the best treatment for the patient. (bvsalud.org)
  • The patient received adjuvant third-generation chemotherapy with a taxane and an anthracycline, followed by radiotherapy to the breast, supraclavicular fossa and axilla. (cmaj.ca)
  • However it seems that in the progression of breast cancer up to 60% of patients will develop liver metastases, 20% of them being estimated to be diagnosed within five years from breast surgery. (iiarjournals.org)
  • A total of 847 patients were randomized 2:1 to receive pembrolizumab at 200 mg (n = 566) or placebo (n = 281) every 3 weeks in combination with nab-paclitaxel (Abraxane), paclitaxel, or gemcitabine plus carboplatin. (onclive.com)
  • NICE's decision to recommend pembrolizumab for TNBC builds upon draft guidance published earlier this year, which opened the door for approximately 100 TNBC patients in England and Wales to access Merck & Co/MSD's Keytruda following lengthy debate over the cost effectiveness of the treatment. (pharmaphorum.com)
  • At the time, the patient had no respiratory symptoms or skin findings of sarcoidosis, and her calcium level was within the normal range. (cmaj.ca)
  • Acupuncture has increasingly been used to address a variety of symptoms in patients with cancer. (lidsen.com)
  • Over the recent decades, acupuncture has been recognized and increasingly been used as a non-pharmacological intervention for variety of cancer-associated symptoms in the United States. (lidsen.com)
  • Objectives Electronic patient self-Reporting of Adverse-events: Patient Information and aDvice (eRAPID) is an online system developed to support patient care during cancer treatment by improving the detection and management of treatment-related symptoms. (bmj.com)
  • Patients can complete symptom reports from home and receive severity-based self-management advice, including notifications to contact the hospital for severe symptoms. (bmj.com)
  • It is also indicated as first-line treatment for patients with locally advanced (nonresectable stage II or stage III) or metastatic (stage IV) adenocarcinoma of the pancreas and in patients previously treated with 5-FU. (fresenius-kabi.com)
  • Other milestones include the approval of sacituzumab govitecan-hziy (Trodelvy) for patients with previously treated metastatic TNBC and PARP inhibitors for those with germline BRCA1/2 (g BRCA1/2 ) mutations, Kalinsky said. (onclive.com)
  • This evaluation uses new cost-effectiveness estimates to update olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer (NICE technology appraisal guidance TA831). (bvsalud.org)
  • Evidence-based recommendations on olaparib (Lynparza) for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer in adults. (bvsalud.org)
  • Cost-effectiveness of DPYD Genotyping Prior to Fluoropyrimidine-based Adjuvant Chemotherapy for Colon Cancer. (cdc.gov)
  • Design, Setting, and Patients: Retrospective analysis of German and US cohorts of patients treated with adjuvant tamoxifen for early stage breast cancer. (elsevierpure.com)
  • PHASE I (CYCLES 1-3): Patients receive ruxolitinib phosphate orally (PO) twice daily (BID) on days 1-21, paclitaxel intravenously (IV) over 1 hour on days 1, 8, and 15, and carboplatin IV over 30 minutes on day 1. (uchicagomedicine.org)
  • FDA medical oncologists discuss the January 12, 2018, approval of olaparib, the first PARP inhibitor approved for the treatment of patients with metastatic breast cancer with a germline BRCA mutation. (fda.gov)
  • Patients should be selected for treatment with olaparib based on the results of an FDA-approved companion diagnostic test for the presence of a deleterious germline BRCA mutation. (fda.gov)
  • The approval also includes men with metastatic HER-2 negative, germline BRCA mutated breast cancer. (fda.gov)
  • So, the approval of olaparib for these patients represents the first PARP inhibitor approved for the treatment of patients with metastatic breast cancer with a germline BRCA mutation. (fda.gov)
  • Cancer cells can be deficient in homologous recombination repair mechanisms, which can be caused by BRCA mutations as well as potentially several other deleterious genetic changes. (fda.gov)
  • Now in the event thats in Japan with BRCA -mutated, metastatic knocker cancer unfashionable on also attired in b be allocated to the opportunity to profit from LYNPARZA. (piwip.com)
  • Context: The growth inhibitory effect of tamoxifen, which is used for the treatment of hormone receptor-positive breast cancer, is mediated by its metabolites, 4-hydroxytamoxifen and endoxifen. (elsevierpure.com)
  • These cancer cells have proteins on the outside of their walls called hormone receptors. (knowbreastcancer.org)
  • At the final analysis of the study, there was not an improvement in OS for patients who received KEYTRUDA plus LENVIMA compared to docetaxel. (streetinsider.com)
  • Moreover, our immunohistochemical studies of biopsies performed on patients with micrometastatic BM involvement show that dormant metastases reside adjacent to SDF-1+ vasculature. (grantome.com)
  • Speaking about the promise of liquid biopsies in breast cancer, Sarah-Jane Dawson, the PhD group leader of the Cancer Therapeutics Program at Peter MacCallum Cancer Centre, Victoria, Australia, said she didn't think that ctDNA would replace tissue biopsies, but tissue biopsies clearly have limitations that include being invasive and difficult to perform serially. (medscape.com)
  • Breast cancer is the number one cancer diagnosed amongst South African women with a 1 in 29 lifetime risk [ 2 , 3 ], while prostate cancer is the most prevalent in men [ 4 ]. (hindawi.com)
  • includes prostate cancer, for which generation" [11]. (who.int)
  • Intervention Patients were asked to use the eRAPID intervention and complete weekly online symptom reports during four cycles of chemotherapy. (bmj.com)
  • Patients with bone metastases are often treated with osteoclast inhibitors, as these agents have been shown to reduce the risk of skeletal related events such as fractures, the need for surgery or radiation to bone, spinal cord compression, and hypercalcaemia of malignancy. (biomedcentral.com)
  • She works collaboratively with Mount Sinai breast surgeons, radiation oncologists, radiologists, and other related subspecialists to provide care to breast cancer patients and conduct breast cancer research. (mssm.edu)
  • In order to achieve a more effec- were recommended postoperative radiation and adjuvant tive and individualised chemotherapeutic treatment of breast chemotherapy. (lu.se)